Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Fluorodeoxyglucose F18
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Protein Kinases
  • Sirolimus

abstract

  • These observations demonstrate that inhibition of glucose metabolism is an early effect of everolimus treatment in NSCLC patients and can be assessed using (18)F-FDG PET.

publication date

  • November 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.2967/jnumed.109.065367

PubMed ID

  • 19837761

Additional Document Info

start page

  • 1815

end page

  • 9

volume

  • 50

number

  • 11